Baloxavir marboxil significantly reduced the likelihood of influenza transmission from the infected patient to the household contacts. Treatment with baloxavir marboxil significantly reduced the risk ...

It is not inevitable that H5N1 will develop into a pandemic -- if we act now. Unfortunately, instead of urgent action, we ...

Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected ...

Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses: Basel Friday, September 20, 2024, 09:00 Hrs [IST] Roche announc ...

Roche's phase 3 CENTERSTONE study shows Xofluza (baloxavir marboxil) significantly reduces influenza transmission in ...

Roche today released positive top-line results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an ...

According to the company, the results are the first time an antiviral drug has reduced transmission of a respiratory virus in ...

Roche (RHHBF) unit Genentech said Xofluza antiviral reached the main goal in a global Phase 3 trial, reducting the ...

Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE ...

Roche said its Xofluza treatment reduced the spread of influenza in a single dose during a Phase 3 trial, meeting its main goal. The Swiss pharma giant said Thursday that a single oral dose of Xofluza ...

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household membersThis is the first time that any antiviral used in the treatment ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...